Palvella Therapeutics, Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Palvella Therapeutics, Inc. (PVLA) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-02.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2022-03-02
- Palvella Therapeutics, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2021 was $0.00.
- Palvella Therapeutics, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2020 was -$471.00K, a 140.57% decline from fiscal 2019.
- Palvella Therapeutics, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2019 was $1.16M, a 29.68% decline from fiscal 2018.
- Palvella Therapeutics, Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2018 was $1.65M.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-02 |
| 2020-12-31 | -$471.00K 10-K · filed 2022-03-02 |
| 2019-12-31 | $1.16M 10-K · filed 2021-03-31 |
| 2018-12-31 | $1.65M 10-K · filed 2020-03-13 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |